Alumis Website, Blog & Press Pages

Alumis Website, Blog & Press Pages - aVenture

Alumis - Library

alumis.comCrawled Oct 15, 2026

6 pages

A-005/pipeline/a-005
A-005 is the first allosteric tyrosine kinase 2 (TYK2) inhibitor with demonstrated ability to cross the human blood-brain barrier, enabling targeted treatment within the CNS and periphery.
Envudeucitinib for Psoriasis/pipeline/envudeucitinib-for-psoriasis
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor designed to correct immune dysregulation across a range of diseases, including plaque psoriasis.
Envudeucitinib for SLE/pipeline/envudeucitinib-for-SLE
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor designed to correct immune dysregulation across a range of diseases, including SLE.
Lonigutamab/pipeline/lonigutamab
Lonigutamab is a next-generation anti–insulin-like growth factor 1 receptor (anti-IGF-1R) —a humanized IgG1 monoclonal antibody designed for subcutaneous delivery.

4 pages

About IGF-1R/science/about-igf-1r
The company is developing lonigutamab, an anti–insulin-like growth factor 1 receptor (anti-IGF-1R) monoclonal antibody (mAb).
About TYK2/science/about-TYK2
The company is developing oral TYK2 inhibitors ESK-001 and A-005 for immune-mediated diseases.
Publications and Posters/science/publications-and-posters
The company’s R&D approach targets key drivers of immune dysfunction and uses genetic and translational insights.
science/science
The company uses a data analytics platform that integrates genetic, genomic, proteomic, biological, and clinical insights to support a precision approach to therapeutic development.

2 pages

careers/careers
The company encourages work-life balance and self-care as part of its employee wellness approach.
Job Opportunities at Alumis Inc./careers/job-opportunities
The company seeks people dedicated to teamwork.

1 page

about/about
The company aims to replace broad immunosuppression with targeted therapies to improve patients’ lives.

1 page

Homepage/
The company uses a precision approach to develop therapies for immune-mediated diseases.

5 items

Alumis Announces Topline Results for Envudeucitinib Phase 2b Trialinvestors.alumis.com/news-releases/news-release-details/alumis-announces-topline-results-envudeucitinib-phase-2b-trial
Alumis announces topline results for envudeucitinib Phase 2b LUMUS trial in lupus
Sep 2026 · AlumisNews article
Envudeucitinib Long-Term Data Positioned to Set New Standardinvestors.alumis.com/news-releases/news-release-details/envudeucitinib-long-term-data-positioned-set-new-standard-plaque/
Alumis reports long-term ONWARD3 data for envudeucitinib in plaque psoriasis. The headline says the data position the drug to set a new standard, but provides no specific study findings.
Aug 2026 · AlumisNews article
Alumis Announces Pricing of Upsized Public Offeringinvestors.alumis.com/news-releases/news-release-details/alumis-announces-pricing-upsized-public-offering-common-stock/
Alumis announces pricing of upsized public offering of common stock
Jan 2026 · AlumisNews article
Alumis Envudeucitinib Delivers Leading Skin Clearanceinvestors.alumis.com/news-releases/news-release-details/alumis-envudeucitinib-delivers-leading-skin-clearance-among-next
Alumis reports topline results from its Phase 3 ONWARD trials of envudeucitinib in plaque psoriasis.
Jan 2026 · AlumisNews article